International Clinical Trial: A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464327) titled 'A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations' on March 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Hansoh BioMedical R&D Company

Condition: Non-Small Cell Lung Cancer

Intervention: Drug: HS-20093

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: March 31, 2026

Target Sa...